BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, May 27, 2026
Home » Topics » Conferences

Conferences
Conferences RSS Feed RSS

A DNA double helix rests on a print-out illustration of the DNA  base pair letters A, T, C and G.
Biomarkers

Dominant negative IKZF2 variants linked to a new genetic syndrome

Nov. 8, 2023
IKZF2 encodes the critical zinc fingers 2 and 3, which are responsible for the DNA binding activity of Helios. Researchers from the University of British Columbia and affiliated organizations have identified new de novo dominant negative variants of the IKZF2 gene.
Read More
Test tubes, dropper
Immuno-oncology

First-in-class drug-Fc conjugate shows efficacy in preclinical cancer models

Nov. 8, 2023
CD73 (NT5E) contributes to cancer cell proliferation, migration and tumor angiogenesis by limiting immune response in the tumor microenvironment.
Read More
Immuno-oncology

LNK-101, a new T-cell engager targeting CD3 and mesothelin

Nov. 8, 2023
Mesothelin (MSLN) is an attractive immuno-oncology target as it is overexpressed by many cancers with limited expression in normal tissues.
Read More
Professor Ian Frazer, inventor of the Gardasil vaccine

Ausbiotech 2023: Investors riff about bridging gaps in Aussie biotech ecosystem

Nov. 7, 2023
By Tamra Sami
What’s it going to take for Australia’s biotech industry to be more self-sufficient? Although Australia is far away from the rest of the world, no one is an island when it comes to biotechnology, Ausbiotech CEO Lorraine Chiroiu said during the Ausbiotech 2023 conference held in Brisbane Nov. 1-3. Investors gathered to riff about what they were looking for in Australian biotech investments and what needs to change for the sector to be sustainable. All agreed that the science in Australia is top-notch but that the ecosystem needs more investment to be competitive.
Read More

Ausbiotech 2023: Big pharma sees promise in building mRNA platform in Australia to serve APAC

Nov. 7, 2023
By Tamra Sami
Multinational pharma companies like Moderna Inc. and Sanofi SA are setting up mRNA R&D centers in Australia and are banking on the country’s decades of mRNA expertise to bring new therapeutics to the clinic and to serve as regional hubs in Asia Pacific, speakers said during the Ausbiotech 2023 conference held Nov 1-3 in Brisbane, Australia.
Read More
Ausbiotech 2023

Ausbiotech 2023: Australia invests in mRNA vaccines as biotech industry celebrates DNA milestones

Nov. 7, 2023
By Tamra Sami
Australia has a lot to celebrate when it comes to vaccines. The University of Queensland is where Ian Frazer invented the human papillomavirus vaccine Gardasil, and now Australia is projected to be the first in the word to eliminate cervical cancer, Queensland Deputy Premier Steven Miles said during the Ausbiotech 2023 conference held Nov. 1-3 in Brisbane, Australia.
Read More
Macrophage and cancer cell
Immuno-oncology

AZD-2796, a new myeloid checkpoint inhibitor targeting LILRB2

Nov. 7, 2023
Myeloid cells expressing LILRB2 are abundant in the tumor microenvironment and can both drive cancer progression and hinder immune responses. Thus, targeting LILRB2 offers a potential strategy to boost immune-based cancer therapies, as it counteracts their suppressive effects on pro-inflammatory pathways.
Read More
Biomarkers

Mutations in ARHGAP1 involved in severe neurodevelopmental disorder

Nov. 7, 2023
At the recent American Society of Human Genetics meeting, researchers from Stanford University reported clinical and functional evidence of the involvement of ARHGAP1, a Rho GTPase-activating protein (GAP) gene, in a patient exhibiting a syndromic neurodevelopmental disorder.
Read More
3D Rendering of tumor microenvironment
Immuno-oncology

GI-108, an IL-2-based bifunctional agent that restores cytotoxic activity of immunosuppressed immune cells in TME

Nov. 7, 2023
Researchers from GI Innovation Inc. have developed GI-108, a novel bispecific fusion protein designed to augment antitumor immunity.
Read More
Pediatric brain illustration
Biomarkers

De novo variants in DDX39B linked to new neurodevelopmental syndrome

Nov. 7, 2023
The DDX39B gene belongs to the DExD/H-box family of ATP-dependent RNA helicases, playing a vital role in mRNA processing. DDX39B is a component of the TRanscription-EXport (TREX) protein complex, whose pathogenic variants have been recently associated with neurodevelopmental and neurodegenerative disorders.
Read More
Previous 1 2 … 191 192 193 194 195 196 197 198 199 … 3204 3205 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 26, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 26, 2026
  • Microscopy of a cross-section of mouse skin containing melanoma tumors

    Researchers identify innate immune barrier against melanoma

    BioWorld
    Australian researchers have identified a previously overlooked population of immune cells in the skin that physically restrain melanoma growth by engulfing live...
  • Cavalon Therapeutics and Northwestern patent new Cav1.3 blockers

    BioWorld Science
    Cavalon Therapeutics Inc. and Northwestern University have disclosed new voltage-gated calcium channel Cav1.3 blockers potentially useful for the treatment of...
  • Green and red bispecific antibodies

    Biotle’s FcRn inhibitor BTL-203 cleared for clinic in China

    BioWorld Science
    Biotle has received a clinical trial notice from China’s National Medical Products Administration (NMPA) for its IND application for BTL-203, the company’s...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing